Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 16/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5728516 | 0.87 | ELANE (0.46) | ELANECASP1 | |
| SCHEMBL5729023 | 0.83 | ELANE (0.52) | ELANEMEN1KMT2ACASP1CNR2 | |
| SCHEMBL6178282 | 0.82 | ELANE (0.51) | ELANEMEN1KMT2ACNR2 | |
| SCHEMBL5728831 | 0.78 | ELANE (0.42) | ELANEMEN1KMT2ACASP1 | |
| SCHEMBL5728765 | 0.77 | ELANE (0.55) | ELANECASP1 | |
| SCHEMBL6558393 | 0.74 | CTRC (0.68) | ELANE | |
| SCHEMBL2450503 | 0.71 | KMT2A (0.57) | KMT2A | |
| SCHEMBL6085435 | 0.70 | ELANE (0.67) | ELANECASP1 | |
| SCHEMBL5728354 | 0.69 | ELANE (0.61) | ELANE | |
| SCHEMBL5728202 | 0.69 | ELANE (0.54) | ELANECASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060270850-A1 | Processes for preparation of pyrimidine derivatives and intermediates | AJINOMOTO CO., INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1695967-A1 | PROCESSES FOR PRODUCTION OF PYRIMIDINE DERIVATIVES AND INTERMEDIATES | Ajinomoto Co., Inc. (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20050176966-A1 | Process for the preparation of pyrimidine derivative, intermediate therefor and process for the preparation thereof | AJINOMOTO CO., INC. (JP) | 2005-08-11 | — | — | US | disclosed |
| EP-1529778-A1 | Production method of pyrimidine derivative, intermediate therefor | Ajinomoto Co., Inc. (JP) | 2005-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176966-A1 | Process for the preparation of pyrimidine derivative, intermediate therefor and process for the preparation thereof | DPYD, WEE1, DCXR | ELANE 4520/4885MEN1 1538/4885KMT2A 2880/4885 |
| US-20060270850-A1 | Processes for preparation of pyrimidine derivatives and intermediates | PDXK, RNASEL, DPYD | ELANE 4219/4885MEN1 3414/4885KMT2A 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.